Gene and Cell Therapy Breakthroughs in China – RNA Editing, Chemical Reprogramming, and iPSC-Derived Therapies

From first-in-human RNA editing for Duchenne muscular dystrophy to fully automated chemical reprogramming of stem cells, China is pioneering the next generation of gene and cell therapies.

I. Introduction: China's Ascent in Gene and Cell Therapy

China has emerged as a global powerhouse in gene and cell therapy, with a pipeline that rivals — and in some areas surpasses — that of the United States and Europe. As of mid-2026, China has over 30 IND applications for gene and cell therapy products under active review by the NMPA, spanning indications from rare genetic disorders to common cancers.

What distinguishes China's approach is its breadth of technological platforms: from CRISPR-Cas9 gene editing and RNA editing to induced pluripotent stem cell (iPSC) differentiation and chemical reprogramming, Chinese researchers and companies are exploring every major frontier in advanced therapeutics.

This article reviews the most significant breakthroughs in China's gene and cell therapy sector in 2026, focusing on three areas: RNA editing for muscular dystrophy, chemical reprogramming of stem cells, and iPSC-derived cell therapies for neurodegenerative diseases.

I. RNA Editing: The LEAPER Platform for Duchenne Muscular Dystrophy

The Technology: From Research to First-in-Human Clinical Study

In June 2026, a research team from Changping Laboratory and Peking University, led by Professor Wei Wensheng, announced the first-in-human clinical study of their LEAPER (Leveraging Endogenous ADAR for Programmable Editing of RNA) technology for the treatment of Duchenne muscular dystrophy (DMD). This marks the first-ever clinical application of an RNA-editing strategy for DMD.

Duchenne muscular dystrophy is a devastating X-linked genetic disorder caused by mutations in the DMD gene, which encodes dystrophin — a protein essential for muscle fiber integrity. The disease affects approximately 1 in 3,500–5,000 male births worldwide, leading to progressive muscle degeneration and premature death typically by the third decade of life.

Unlike DNA-editing approaches such as CRISPR-Cas9, which permanently alter the genome, LEAPER achieves transient, reversible RNA editing by recruiting endogenous ADAR (adenosine deaminase acting on RNA) enzymes to specific target sites on messenger RNA. The edited RNA, in turn, produces a functional dystrophin protein.

Clinical Results: Sustained Motor Function Improvement in Three Patients

The first three patients treated with the LEAPER-based therapy — all boys aged 6–10 years with confirmed DMD mutations — demonstrated:

• Sustained improvement in motor function as measured by the 6-minute walk test and North Star Ambulatory Assessment, with benefits persisting for more than 6 months after treatment
• Increased respiratory muscle strength, a critical endpoint that correlates with survival in DMD patients
• No serious adverse events reported to date, with all patients tolerating the therapy well

Professor Wei Wensheng commented: "This is the first demonstration that RNA editing can achieve clinically meaningful benefit in a genetic neuromuscular disease. The potential of this technology extends far beyond DMD — we are already exploring applications in other genetic disorders where transient protein restoration is sufficient for therapeutic benefit."

Why This Matters

RNA editing offers several advantages over DNA editing for certain indications:

• Reversibility: Unlike DNA editing, which permanently alters the genome, RNA editing can be stopped if safety concerns arise
• Lower immunogenicity: LEAPER uses endogenous ADAR enzymes, avoiding the immunogenicity associated with exogenous proteins like Cas9
• Applicability to a broad range of mutations: The technology can be targeted to different RNA sequences, making it potentially applicable to many genetic disorders

II. Chemical Reprogramming of Stem Cells: The Fully Automated Platform

In July 2026, the team led by Professor Deng Hongkui at Peking University unveiled a major advance: the world's first fully automated platform for chemical reprogramming of stem cells — the Intelligent Cell Chemical Reprogramming and Clonal Screening Platform.

Chemical reprogramming is a revolutionary approach to generating induced pluripotent stem cells (iPSCs) without genetic manipulation. Instead of introducing foreign genes (as in the classical Yamanaka method), chemical reprogramming uses small molecules to reset the epigenetic state of somatic cells, converting them to a pluripotent state.

Breakthroughs Achieved

The automated platform, developed in collaboration with Hunan Zhaotai Medical Technology Co., Ltd., integrates robotics and artificial intelligence to achieve:

• "From blood to stem cells" — automated processing of a peripheral blood sample into iPSCs within a closed, sterile system
• Clone selection and quality control using AI-powered imaging and microfluidic sorting
• Reduced manufacturing cost by eliminating the need for expensive viral vectors and skilled manual labor

This platform has already been validated in the production of chemically reprogrammed iPSC-derived pancreatic islet cells for type 1 diabetes therapy, which the Deng team previously demonstrated restored glucose homeostasis in non-human primates and has now entered human clinical trials.

Clinical Validation: Islet Cell Transplantation for Type 1 Diabetes

In a study published in Cell and widely reported in 2025–2026, the Deng team reported that patients with type 1 diabetes who received chemically reprogrammed iPSC-derived islet cells showed:

• Restored glucose-regulated insulin secretion within weeks of transplantation
• Sustained glucose control lasting nearly 3 years without exogenous insulin in the first patient
• No evidence of teratoma formation or other safety concerns to date

The automated platform now makes this therapy scalable, potentially democratizing access to cell-based diabetes treatments.

III. iPSC-Derived Cell Therapy: Parkinson's Disease and Beyond

The UX-DA001 Program for Parkinson's Disease

In May 2026, Shanghai-based YueSai Biotech announced that its iPSC-derived dopaminergic neuron precursor cell therapy, UX-DA001, had received approval from China's Center for Drug Evaluation (CDE) to initiate a Phase I clinical trial for the treatment of Parkinson's disease.

UX-DA001 is the first iPSC-derived cell therapy for Parkinson's disease to receive clinical trial approval in China, and one of the first in the world to advance to human trials. The therapy uses chemically reprogrammed iPSCs differentiated into dopaminergic neuron precursors, which are surgically transplanted into the striatum of Parkinson's patients.

Clinical Progress

The Phase I trial, being conducted at Ruijin Hospital in Shanghai, has already enrolled and treated its first patients. Early safety data indicate:

• No serious adverse events related to the graft or surgical procedure
• Mild, transient dyskinesia in some patients, which resolved spontaneously
• Early signs of motor improvement as measured by the Unified Parkinson's Disease Rating Scale (UPDRS), though efficacy assessment remains preliminary

Broader iPSC Pipeline

Beyond Parkinson's disease, Chinese companies are developing iPSC-derived therapies for:

• AMD (age-related macular degeneration) — retinal pigment epithelium (RPE) cell therapy
• Spinal cord injury — oligodendrocyte progenitor cell therapy
• Myocardial infarction — cardiomyocyte transplantation

IV. CRISPR-Cas9 Gene Editing: Advancing Toward Clinical Use

While RNA editing and chemical reprogramming represent cutting-edge approaches, CRISPR-Cas9 gene editing continues to advance in China, with multiple IND approvals and clinical trials underway.

Ex Vivo CRISPR Therapies

• BRL-101 (BRL Med) — CRISPR-edited hematopoietic stem cells for transfusion-dependent β-thalassemia; Phase I/II trial ongoing
• ET-01 (EdiGene) — CRISPR-edited CD34+ stem cells for β-thalassemia; Phase I trial in China and U.S.

In Vivo CRISPR Therapies

• CRISPR-Cas9 editing for inherited retinal diseases — multiple preclinical programs
• In vivo liver editing — for metabolic disorders including hereditary tyrosinemia and Pompe disease

V. Regulatory Environment for Gene and Cell Therapy in China

China has developed a comprehensive regulatory framework for gene and cell therapy, which has been instrumental in accelerating clinical development:

• Specific Guidelines for Cell Therapy Products — NMPA issued dedicated guidelines in 2023, updated in 2025, covering all aspects of cell therapy development
• IND 30-Day Silent Approval — Gene and cell therapy clinical trial applications benefit from the streamlined 30-day silent approval pathway
• Priority Review — Therapies for serious diseases with no satisfactory treatment options are eligible for priority review
• Conditional Approval — Therapies demonstrating compelling early-phase data can receive conditional approval for marketing

VI. What This Means for International Patients

For international patients considering treatment in China, the gene and cell therapy sector offers:

• Access to world-first therapies — including the LEAPER RNA editing platform and chemical reprogramming-based cell therapies
• Clinical trial participation — opportunities to access promising therapies before they are commercially available
• Cost advantages — gene and cell therapies in China are priced significantly lower than in the U.S. or Europe, while maintaining quality standards
• Expertise — China now has some of the world's leading researchers in stem cell biology and gene editing

Conclusion

China's gene and cell therapy sector has undergone a remarkable transformation in 2026. From the first-in-human RNA editing therapy for DMD to the fully automated chemical reprogramming platform for iPSC generation, and from iPSC-derived cell therapy for Parkinson's disease to advancing CRISPR programs, China is no longer following global trends — it is setting them.

As one industry observer noted: "China has moved from being a low-cost manufacturer of biosimilars to a first-in-class innovator in gene and cell therapy."